A practical reference on 合成七肽: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-20 and is reviewed periodically as new material appears.
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
| Property | Value | Notes |
|---|---|---|
| 结构类别 | 线性合成七肽 | 无环化结构，不含二硫键 |
| 氨基酸序列 | Met-Glu-His-Phe-Pro-Gly-Pro | N 端为甲硫氨酸 |
| 分子量 | 约 814 Da | 游离碱形式的计算值 |
| 外观 | 白色至类白色粉末 | 具吸湿性 |
| 溶解性 | 易溶于水 | 亦可溶于甲醇等极性溶剂 |
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
=== Determination of protein sequences === With their success in improving the analysis time for amino acids, Stein and Moore began to determine the structure of an entire protein molecule, specifically bovine ribonuclease, in the early 1950s. They determined the entire sequence of ribonuclease by 1960. This sequence combined with X-ray analysis of the crystallized ribonuclease lead to the determination of the nuclease's active site. Stein won a Nobel Prize in Chemistry in 1972 with Moore and Christian Boehmer Anfinsen, for their work on ribonuclease and "for their contribution to the understanding of the connection between chemical structure and catalytic activity of the ribonuclease molecule."
[b]oth hot-iron and freeze branding cause acute pain in the first 1.5 h after branding as shown by the marked increase in cortisol. The more pronounced and prolonged elevation of cortisol observed in H animals implies that hot-iron branding may be initially (up to 40 min after branding) more distressing than freeze branding. However, there appeared to be no differences after the 40 min sampling time suggesting that the discomfort caused by both methods is relatively short lived.
== Society and culture == The direct economic costs of PMOS in the United States are estimated to be over $15 billion per year (in 2021 USD). This includes the costs of managing PMOS, treating its complications such as strokes, and its mental health costs. Compared to arthritis and lupus—diseases with a similar or lower prevalence and similar severity—PMOS received lower NIH research funding between 2005 and 2015. Australia likewise saw a low number of grants. This possible underfunding reflects a gender bias in health care, where conditions mostly affecting women receive less research funding. There is substantial misinformation on PMOS in social media. For example, some health influencers promote restrictive diets, such as eliminating gluten or dairy, for which there is no evidence of effectiveness. Others recommend against intensive cardiovascular exercise, despite its usefulness. Some social media influencers without medical qualifications, including those with large followings, have presented themselves as authorities on PMOS to promote their unproven treatments, taking advantage of the limited medical options available for treating the condition. Research has identified notable gaps in physician knowledge and education related to PMOS, which may contribute to challenges in timely diagnosis and treatment. For instance, health care professionals in primary care, but also in gynecology and reproductive specialists, are often unfamiliar with the precise diagnostic criteria.
Sources: en.wikipedia.org
Even though this reaction proceeds effectively at biological conditions, copper in this range of dosage is cytotoxic. Solutions to this problem have been presented, such as using water-soluble ligands on the copper to enhance cell penetration of the catalyst and thereby minimize the dosage needed, An analogous "RuAAC reaction" (catalyzed by ruthenium, instead of copper) allows for the selective production of 1,5-isomers.
=== Australia === In-N-Out Burger has also had other similarly named imitators in Australia that confuse consumers into thinking that the businesses is associated with the Californian-based chain. The company would take the imitators to court for trademark infringement and has opened one-day pop-ups in Sydney in 2012, 2013, 2016, 2017, 2019, and 2022; Brisbane in 2020; Melbourne in 2014 and 2018; and Perth in 2018 and 2022 to preserve their trademark rights. Customers may wait for several hours before the doors open, but the food would run out very quickly, sometimes in less than hour after opening. Although In-N-Out may not have plans to open a permanent location outside its current operating region, the business strategy of having one-day pop-ups is to maintain a business presence in the country under Australian trademark law without opening a permanent restaurant. In-N-Out successfully defended their trademarks and intellectual property rights in Australia in 2020 against Hashtag Burgers Pty Ltd, formerly doing business as "Funk N Burgers" and "Down-N-Out Burger". In 2021, In-N-Out filed a lawsuit against Queensland-based Rich Asians Pty Ltd doing business as "In & Out Aussie Burgers".
== SY == SY – (s) Syria (ISO 3166 and FIPS 10-4 country code digram) SYC – (s) Seychelles (ISO 3166 trigram) SYLK – Microsoft 'Symbolic Link' data file format SYP – (s) Syrian pound (ISO 4217 currency code) SYR – (s) Syria (ISO 3166 trigram) Syriza – (p) Synaspismós Rizospastikís Aristerás (Greek Συνασπισμός Ριζοσπαστικής Αριστεράς, "Coalition of the Radical Left") SysML – (p) System Modeling Language Sysop – (p) System Operator
Sources: en.wikipedia.org
不存在。它是依据 ACTH 的一段序列人工设计的分子，天然蛋白质中找不到与之完全相同的七肽。名称属于研究代号，而非天然物质名。
Semax 对应 ACTH 第 4 至第 10 位的片段，并在两端做了替换与延长，使其不再具备促肾上腺皮质激素的典型内分泌活性。这一改动同时改变了它在体内的稳定性与分布特征。
俄罗斯将其列为处方药物，需要医生开具处方。多数其他国家把它当作研究化合物，不能作为药品销售或宣称疗效。具体合法性取决于当地法规。
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.